2014年1-9月美国FDA批准的罕见病用药概况

Overview on orphan drugs approved by FDA from January to September in 2014

罕见病用药的研发能够得到政府政策和财力的支持,同样可使制药公司获得超额利润。随着罕见病用药市场的急剧增长,世界各大制药公司亦纷纷加入罕见病用药的研发行列。本文就美国FDA 2014年1-9月批准的罕见病用药情况作一概要介绍。

Pharmaceutical companies have obtained excessive profits from the policy and funding of various governments specially for the RD of orphan drugs. The global pharmaceutical giants have joined in the ranks of orphan drugs RD with the rapid growth of the market for the medication of rare diseases. This paper introduces the profile of orphan drugs approved by FDA from January to September in 2014.